Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride

Journal of Clinical Pathology

Volumn 64, Issue 9, 2011, Pages 756-760

  Sumida, Keiichi ^a   Nakamura, Michio ^a   Ubara, Yoshifumi ^a   Marui, Yuji ^a   Tanaka, Kiho ^a   Takaichi, Kenmei ^a   Tomikawa, Shinji ^a   Inoshita, Naoko ^a   Ohashi, Kenichi ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; CINACALCET; HEMOSIDERIN; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; VITAMIN D;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLEEDING; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMODIALYSIS PATIENT; HEMOSIDEROSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROSCOPY; ORGAN WEIGHT; PARATHYROID GLAND; PARATHYROIDECTOMY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; SCORING SYSTEM; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION;

CELL COUNT; DRUG RESISTANCE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPLASIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; ORGAN SIZE; OXYPHIL CELLS; PARATHYROID GLANDS; RENAL DIALYSIS;

EID: 80051869121     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200100     Document Type: Article

References (22)

1. National Kidney Foundation. K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(4 Suppl 3):S1-201.
2. De Francisco A.L. Secondary hyperparathyroidism: Review of the disease and its treatment. Clin Ther 2004;26:1976-1993 (Pubitemid 40353608)
3. Rostand S.G., Druke T.B. Parathyroid hormone vitamin D, and cardio-vascular disease in chronic renal failure. Kidney Int 1999;56:383-392 (Pubitemid 29353135)
4. Tentori F., Blayney M.J., Albert J.M., et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphate, and PTH: The Dialysis Outcomes and Practice Study (DOPPS). Am J Kidney Dis 2008;52:519-530
5. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008;12:514-525
6. Nemeth E.F., Heaton W.H., Miller M., et al. Pharmacodynamics of the type two calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004;308:627-635 (Pubitemid 38134225)
7. Block G.A., Martin K.J., De Francisco A.L., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-1525 (Pubitemid 38477776)
8. Lindberg JS, ulleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-807
9. Messa P., Macario F., Yaqoob M., et al. The OPTIMA study: Assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36-45.
10. Meola M., Petrucci I., Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009;24:982-989
11. Lomonte C., Vernaglione L., Chimienti D., et al. Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism? Clin J Am Soc Nephrol 2008;3:794-799
12. Basile C., Lomonte C., Vernaglione L., et al. A high body mass index and female gender are associated with an increased risk of nodular hyperplasia of parathyroid glands in chronic uremia. Nephrol Dial Transplant 2006;21:968-974
13. Drueke T., Martin D., Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 2007;22:1828-1839 (Pubitemid 47244749)
14. De Francisco A.L. Cinacalcet HCl: A novel therapeutic for hyperparathyroidism. Expert Opin Pharmacother 2005;6:441-452
15. Lomonte C., Antonelli M., Losurdo N., et al. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy. Nephrol Dial Transplant 2007;22:2056-2062 (Pubitemid 47244781)
16. Rodriguez M., Nemeth E., Martin D. The calcium-sensing receptor: A key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005;288:F253-F264 (Pubitemid 40105383)
17. Moe S.M., Cunningham J., Bommer J., et al. Long term treatment of secondary hyperparathyroidism with the calcimimetics cinacalcet HCl. Nephrol Dial Transplant 2005;20:2186-2193 (Pubitemid 41510096)
18. Pavlovic D. Prevention and treatment of secondary hyperparathyroidism: Still a challenge for the nephrologist? Nephrol Dial Transplant 2003;18:S45-S46
19. Schoming M., Ritz E. Management of disturbed calcium metabolism in uraemic patients: 2. Indications for parathyroidectomy. Nephrol Dial Transplant 2000;15(Suppl 5):S25-S29
20. Tominaga Y., Tanaka Y., Sato K., et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997;13:78-86. (Pubitemid 27146980)
21. Mizobuchi M., Ogata H., Hatamura I., et al. Activation of calcium-sensing receptor accelerates apoptosis in hyperparathyroid cells. Biochem Biophys Res Commun 2007;362:11-16. (Pubitemid 47296286)
22. Wada M., Nagano N. Control of parathyroid cell growth by calcimimetics. Nephrol Dial Transplant 2003;18(Suppl 3):S13-S17